Nutlin-3a Inhibits p53-Hdm2 Interaction to Prevent PVR Recurrence

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for proliferative vitreoretinopathy (PVR) are largely surgical and have limited success, with no effective non-surgical options available to prevent or reduce the severity of the disease, which affects 5-11% of patients undergoing rhegmatogenous retinal detachment surgery and carries a high risk of recurrence.

Innovation Solution

Administering the small molecule Nutlin-3, which inhibits the interaction between p53 and Hdm2, to reduce intra-ocular p53 levels, thereby preventing retinal detachment and reducing the severity of PVR through intravitreal or subconjunctival administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgical treatment is used for PVR, then anatomical success rate is improved (60-80%), but the risk of recurrence remains high and multiple surgeries may be needed

Engineering Contradiction:

Improveanatomical success rateVSAvoidrecurrence risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by administering Nutlin-3a before or during surgical intervention to prevent the development of PVR. By stabilizing p53 levels in advance, the treatment aims to prevent cellular proliferation and membrane formation that would otherwise require surgical removal, thereby reducing recurrence risk and potentially eliminating the need for repeat surgeries.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses Nutlin-3a as an intermediary substance that mediates between the harmful effects of retinal detachment and the desired anatomical repair. The compound acts as a molecular mediator that stabilizes p53 to inhibit the pathological cellular responses (proliferation, migration, and membrane formation) that lead to PVR recurrence, providing a pharmacological bridge that complements surgical intervention.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If no pharmacological treatment is available, then surgical options remain the only choice, but this limits treatment effectiveness and increases patient burden

Engineering Contradiction:

Improvetreatment optionsVSAvoidpatient burden

Core Design Contradiction:

Adaptability or versatilityVSEase of operation

Solution Approach 1:

The patent applies mechanics substitution by replacing the purely mechanical/surgical approach with a pharmacological intervention. Instead of relying solely on surgical manipulation to address PVR, the invention introduces Nutlin-3a as a chemical agent that targets the molecular mechanisms (p53 degradation) underlying PVR pathogenesis, thereby expanding treatment options and reducing the need for invasive repeat procedures.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent employs parameter changes by altering the biochemical parameter of p53 stability within the ocular environment. By administering Nutlin-3a to prevent p53 degradation, the treatment changes the molecular landscape of the eye, inhibiting the cellular processes that drive PVR. This parameter change provides a new therapeutic dimension that complements or reduces the need for surgical intervention.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If p53 levels are reduced in the eye, then cellular proliferation increases leading to PVR, but maintaining normal p53 levels is essential for preventing this pathological process

Engineering Contradiction:

Improveprevention of retinal detachmentVSAvoidp53 level

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies preliminary anti-action by administering Nutlin-3a to counteract the pathological reduction of p53 levels before they can lead to uncontrolled cellular proliferation. The compound acts in advance to stabilize p53 and prevent the cascade of events (cell migration, proliferation, and membrane formation) that characterize PVR, thereby maintaining protective p53 levels throughout the disease process.

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Nutlin-3 effectively prevents retinal detachment and reduces the severity of PVR by maintaining elevated p53 levels, as demonstrated in animal models and human PVR membranes, offering a non-surgical therapeutic option for this blinding disease.

Implementation Method 1

Administering the small molecule Nutlin-3, which inhibits the interaction between p53 and Hdm2, to reduce intra-ocular p53 levels

Methodology Applied

Scientific EffectProtein-protein interaction inhibition:

Data Source

PatentUS11464773B2Nutlin-3a for treatment of proliferative vitreoretinopathy

Publication Date: 2022.10.11 SCHEPENS EYE RESEARCH INSTITUTE INC

AI summary

The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.